Table 2.

Baseline characteristics of the AdRA cohort and the 11 trial projection groups. Data are number (SD) unless otherwise indicated.

Projection Group	Trial	N	DAS28, t = 0 (SD)	Swollen Joints^†	Tender No. Joints^†	Previous DMARD
	AdRA cohort	168	5.13 (1.2)	7.9 (5.9)	7.5 (6.5)	3.2 (1.4)
A	Atzeni 2006²⁰	168	5.13 (1.2)	7.9 (5.9)	7.5 (6.5)	3.2 (1.4)
B	Rau 2004²¹	159	5.23 (1.2)	8.1 (6.0)	7.9 (6.5)	3.2 (1.5)
C^*	Barrera 2002²²^*	161	5.20 (1.2)	8.0 (6.0)	7.8 (6.4)	3.2 (1.4)
D	Den Broeder 2002²³	159	5.23 (1.2)	8.1 (6.0)	7.9 (6.5)	3.2 (1.5)
E	Bennett 2005²⁴	95	5.90 (1.0)	11.6 (6.0)	13.1 (6.5)	3.3 (1.5)
F^*	Weisman 2003²⁵^*	57	6.26 (1.0)	11.9 (5.9)	12.7 (5.8)	3.3 (1.5)
G	Furst 2003¹⁰	58	6.18 (1.0)	10.1 (6.4)	10.7 (6.6)	3.5 (1.5)
H	Weinblatt 2003^{9,26^†}	39	6.37 (0.9)	11.8 (6.3)	11.2 (6.2)	2.8 (0.9)
I^*	Keystone 2004²⁷^*	36	6.27 (1.0)	12.9 (5.8)	12.2 (5.0)	3.7 (1.6)
J	Breedveld 2006²⁸	34	6.39 (1.0)	13.2 (6.2)	13.1 (5.5)	3.4 (1.4)
K	Van de Putte 2004^{29,30^†}	22	6.38 (1.0)	15.9 (5.8)	15.3 (6.2)	3.5 (1.6)

↵* Trials selected for pairwise comparison of outcomes.
↵† 0–28 joints. AdRA: large prospective cohort of patients with RA treated with adalimumab; DAS28: 28-joint Disease Activity Score; DMARD: disease-modifying antirheumatic drugs.